Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100PLTQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥344.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥172.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥65.9bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥29.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥65.3bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥29.3bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥50.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥22.1bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥50.0bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥22.1bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥1.66Tat 2022-09-30Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.37Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥461.4bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥904.0bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥856.7bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥904.0bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥202.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥66.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥40.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥25.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥117.452021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥66.112021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥29.222021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥117.382021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥66.072021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥29.22021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.0%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-09-30¥124m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥1.8bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥58.2bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥11.8bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥194.3bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥50.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥92.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥13.4bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥344.5bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥76.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 696
ItemContextValueUnit
Profit loss before tax IFRSCurrentYTDDuration54624000000JPY
Income tax expense IFRSPrior1YTDDuration15294000000JPY
Income tax expense IFRSCurrentYTDDuration14303000000JPY
Profit loss IFRSPrior1YTDDuration49988000000JPY
Profit loss IFRSCurrentYTDDuration40321000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration49988000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration40321000000JPY
Profit loss IFRSPrior1YTDDuration49988000000JPY
Profit loss IFRSCurrentYTDDuration40321000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration66.11
Basic earnings loss per share IFRSCurrentYTDDuration53.37
Diluted earnings loss per share IFRSPrior1YTDDuration66.07
Diluted earnings loss per share IFRSCurrentYTDDuration53.35
Revenue IFRSPrior1QuarterDuration172921000000JPY
Revenue IFRSCurrentQuarterDuration205976000000JPY
Cost of sales IFRSPrior1QuarterDuration80935000000JPY
Cost of sales IFRSCurrentQuarterDuration100620000000JPY
Gross profit IFRSPrior1QuarterDuration91985000000JPY
Gross profit IFRSCurrentQuarterDuration105355000000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration62075000000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration76142000000JPY
Other income IFRSPrior1QuarterDuration564000000JPY
Other income IFRSCurrentQuarterDuration1375000000JPY
Other expenses IFRSPrior1QuarterDuration851000000JPY
Other expenses IFRSCurrentQuarterDuration5038000000JPY
Operating profit loss IFRSPrior1QuarterDuration29623000000JPY
Operating profit loss IFRSCurrentQuarterDuration25549000000JPY
Finance income IFRSPrior1QuarterDuration324000000JPY
Finance income IFRSCurrentQuarterDuration414000000JPY
Finance costs IFRSPrior1QuarterDuration979000000JPY
Finance costs IFRSCurrentQuarterDuration714000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration293000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration-292000000JPY
Profit loss before tax IFRSPrior1QuarterDuration29261000000JPY
Profit loss before tax IFRSCurrentQuarterDuration24957000000JPY
Income tax expense IFRSPrior1QuarterDuration7169000000JPY
Income tax expense IFRSCurrentQuarterDuration7034000000JPY
Profit loss IFRSPrior1QuarterDuration22092000000JPY
Profit loss IFRSCurrentQuarterDuration17922000000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration22092000000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration17922000000JPY
Profit loss IFRSPrior1QuarterDuration22092000000JPY
Profit loss IFRSCurrentQuarterDuration17922000000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration29.22
Basic earnings loss per share IFRSCurrentQuarterDuration23.75
Diluted earnings loss per share IFRSPrior1QuarterDuration29.20
Diluted earnings loss per share IFRSCurrentQuarterDuration23.74
Profit loss IFRSPrior1YTDDuration49988000000JPY
Profit loss IFRSCurrentYTDDuration40321000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration265000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass